Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage oncology company focused on antibody drug conjugates, and its news flow centers on clinical progress, regulatory developments, and corporate updates. The company’s primary product, ZYNLONTA (loncastuximab tesirine-lpyl), is a CD19-directed ADC approved under accelerated and conditional pathways for certain adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior systemic therapies.
News about ADCT commonly includes updates from its LOTIS clinical program, such as the Phase 3 LOTIS-5 trial of ZYNLONTA plus rituximab in second-line or later DLBCL and the Phase 1b LOTIS-7 trial evaluating ZYNLONTA in combination with bispecific antibodies and other agents in B-cell non-Hodgkin lymphoma. Company releases have highlighted response rates, safety findings, and enrollment milestones from LOTIS-7, as well as anticipated timelines for sharing full data and pursuing regulatory and compendia strategies.
Investors and followers of ADCT news will also find announcements on preliminary revenue and cash estimates, participation in healthcare conferences, and equity-related actions such as employee inducement grants and private placements. These items appear in both press releases and related Form 8-K filings, giving context on the company’s commercial performance and financing plans alongside its clinical pipeline.
This news page aggregates such disclosures so readers can track ADCT’s key events, from clinical trial readouts and investigator-initiated study updates in indolent lymphomas to progress on its early-stage PSMA-targeting ADC. For those monitoring ADCT stock, revisiting this page provides a consolidated view of the company’s evolving clinical, regulatory, and corporate narrative.
ADC Therapeutics (NYSE: ADCT) said CEO Ameet Mallik will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2026 at 10:30 a.m. PT. A live webcast will be available via the company’s Investors & Events page and a replay will be accessible for approximately 30 days.
This is a conference presentation notice for investors and stakeholders to access a live and replayed webcast of the CEO remarks.
ADC Therapeutics (NYSE: ADCT) announced an inducement grant of options to purchase 6,000 common shares to a newly hired employee on January 2, 2026.
The grant was approved by the Compensation Committee under the company's Inducement Plan and relied on the NYSE employment inducement exemption (Rule 303A.08). The award vests 25% on the first anniversary and then 1/48th monthly thereafter, fully vesting on the fourth anniversary, subject to continued employment.
ADC Therapeutics (NYSE: ADCT) announced an inducement grant of options to purchase 6,000 common shares to a newly hired employee on January 2, 2026.
The grant was approved by the Compensation Committee under the company's Inducement Plan and relied on the NYSE employment inducement exemption (Rule 303A.08). The award vests 25% on the first anniversary and then 1/48th monthly thereafter, fully vesting on the fourth anniversary, subject to continued employment.
ADC Therapeutics (NYSE: ADCT) reported updated LOTIS-7 Phase 1b data for ZYNLONTA plus glofitamab in r/r DLBCL showing an investigator-assessed ORR 89.8% and CR 77.6% in 49 efficacy-evaluable patients with ≥6 months follow-up.
The combination was described as generally well tolerated with notable safety findings including Grade ≥3 neutropenia in 32.7%, overall CRS 36.7% and two Grade 5 AEs (4.1%) with one deemed treatment-related. Enrollment to ~100 patients at the 150 µg/kg dose is on track for completion in 1H 2026, with full results and a manuscript planned by end of 2026.
ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on December 3, 2025 at 8:00 a.m. EST to provide an update on the LOTIS-7 Phase 1b open-label trial. The trial evaluates safety and efficacy of ZYNLONTA combined with bispecific antibody glofitamab (COLUMVI) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
Participants can register to join by phone (toll-free 1-800-836-8184 for North America and Canada) or via a live webcast on the company's Investors "Events and Presentations" page at ir.adctherapeutics.com. The archived webcast will be available for 30 days after the call.
ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on December 3, 2025 at 8:00 a.m. EST to provide an update on the LOTIS-7 Phase 1b open-label trial. The trial evaluates safety and efficacy of ZYNLONTA combined with bispecific antibody glofitamab (COLUMVI) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
Participants can register to join by phone (toll-free 1-800-836-8184 for North America and Canada) or via a live webcast on the company's Investors "Events and Presentations" page at ir.adctherapeutics.com. The archived webcast will be available for 30 days after the call.
ADC Therapeutics (NYSE: ADCT) announced grants of options to purchase an aggregate of 47,000 common shares to two new employees on December 1, 2025 as inducements for employment. The Compensation Committee approved the grants under the company's Inducement Plan in reliance on the NYSE employment inducement exemption (Rule 303A.08).
The options vest 25% on the first anniversary and then 1/48th monthly thereafter, fully vesting on the fourth anniversary, subject to continued employment.
ADC Therapeutics (NYSE: ADCT) announced grants of options to purchase an aggregate of 47,000 common shares to two new employees on December 1, 2025 as inducements for employment. The Compensation Committee approved the grants under the company's Inducement Plan in reliance on the NYSE employment inducement exemption (Rule 303A.08).
The options vest 25% on the first anniversary and then 1/48th monthly thereafter, fully vesting on the fourth anniversary, subject to continued employment.
ADC Therapeutics (NYSE: ADCT) reported Q3 2025 results and operational updates on Nov 10, 2025. Key items: Q3 product revenue $15.8M and 9M revenue $51.2M; Q3 net loss $41.0M ($0.30/share) and 9M net loss $136.2M ($1.14/share). The company completed a $60M PIPE with estimated net proceeds of $57.6M, which would raise cash to ~$292.3M. Clinical updates: LOTIS-7 data expected by year-end 2025; LOTIS-5 topline expected in 1H 2026; Phase 2 IIT in follicular lymphoma shows ORR 98.2% and CR 83.6% with 12-month PFS 93.9% (median follow-up 28 months). IND-enabling work for PSMA ADC expected complete by end of 2025.
ADC Therapeutics (NYSE: ADCT) reported Q3 2025 results and operational updates on Nov 10, 2025. Key items: Q3 product revenue $15.8M and 9M revenue $51.2M; Q3 net loss $41.0M ($0.30/share) and 9M net loss $136.2M ($1.14/share). The company completed a $60M PIPE with estimated net proceeds of $57.6M, which would raise cash to ~$292.3M. Clinical updates: LOTIS-7 data expected by year-end 2025; LOTIS-5 topline expected in 1H 2026; Phase 2 IIT in follicular lymphoma shows ORR 98.2% and CR 83.6% with 12-month PFS 93.9% (median follow-up 28 months). IND-enabling work for PSMA ADC expected complete by end of 2025.